September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Predicting prevalence and severity of glaucomatous 10-2 visual field loss using 24-2, retinal nerve fiber layer, and macular thickness parameters
Author Affiliations & Notes
  • Michael Sullivan-Mee
    Albuquerque VA Med Center, Albuquerque, New Mexico, United States
  • My Tho Karin Tran
    Albuquerque VA Med Center, Albuquerque, New Mexico, United States
    Ophthalmology, University of New Mexico School of Medicine, Albuquerque, New Mexico, United States
  • Denise Pensyl
    Albuquerque VA Med Center, Albuquerque, New Mexico, United States
  • Suchitra Katiyar
    Albuquerque VA Med Center, Albuquerque, New Mexico, United States
  • Grace Tsan
    Albuquerque VA Med Center, Albuquerque, New Mexico, United States
  • Footnotes
    Commercial Relationships   Michael Sullivan-Mee, None; My Tho Karin Tran, None; Denise Pensyl, None; Suchitra Katiyar, None; Grace Tsan, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 374. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Sullivan-Mee, My Tho Karin Tran, Denise Pensyl, Suchitra Katiyar, Grace Tsan; Predicting prevalence and severity of glaucomatous 10-2 visual field loss using 24-2, retinal nerve fiber layer, and macular thickness parameters. Invest. Ophthalmol. Vis. Sci. 2016;57(12):374.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate which structural and functional parameters are best related to presence and severity of glaucomatous visual field damage measured on the 10-2 visual field test

Methods : Subjects for this investigation were participating in a prospective, longitudinal glaucoma research study at the Albuquerque VA Medical Center. Inclusion required two or more reliable 24-2 and 10-2 VF tests, good quality circumpapillary retinal nerve fiber layer (RNFL) and macular thickness (MT) asymmetry scans obtained within 6 months of the VF tests, and a diagnosis of primary open-angle glaucoma (POAG), ocular hypertension (OH), or glaucoma suspect (GS). Because our objective was to identify which subjects might benefit from 10-2 VF testing, we used the subject as the unit of analysis, with worse-eye measurements used within statistical analyses. Candidate parameters were identified in regression analyses, and then incorporated into receiver operating characteristic (ROC) analyses to determine which factors or combination of factors best predicted presence and severity of 10-2 VF loss.

Results : We studied 180 subjects (97 POAG, 54 OH, 29 GS) and found repeatable 10-2 VF loss in at least one eye of 89 subjects (49%). Multivariate regression analyses identified four parameters (presence of 24-2 VF loss, presence of abnormal 24-2 VF points within 10 degrees of fixation, global RNFL thickness, intra-eye MT asymmetry) that were independently related to presence of 10-2 VF loss (total r-squared=0.68, p<0.001). When thresholds for at least 2 of these 4 factors were exceeded, area under the ROC curve was 0.954, with 90% sensitivity and 92% specificity. In multivariate regression analysis using 10-2 VF mean defect (MD) as the dependent variable, three parameters (24-2 MD, abnormality of at least one of the four 24-2 central points, and rate of 24-2 change over time) were independently related to 10-2 MD (total r-squared=0.83, p<0.001).

Conclusions : Presence and severity of glaucomatous 10-2 VF loss can be reliably estimated using 24-2 VF, RNFL, and MT metrics. These results may be valuable for determining which glaucoma patients will most benefit from 10-2 VF testing.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×